Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis

被引:13
作者
Albiero, Elena [1 ]
Madeo, Domenico [1 ]
Ruggeri, Marco [1 ]
Bernardi, Martina [1 ]
Giorgetti, Alejandro [2 ]
Rodeghiero, Francesco [1 ]
机构
[1] San Bortolo Hosp, Dept Cellular Therapy & Haematol, Vicenza, Italy
[2] Univ Verona, Sci & Technol Dept, I-37100 Verona, Italy
关键词
idiopathic erythrocytosis; polycythemia vera; JAK2 tyrosine kinase; intramolecular auto-inhibition; structural prediction;
D O I
10.1111/j.1365-2141.2008.07180.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report a novel gain-of-function JAK2 exon 12 insertion mutation in a patient with idiopathic erythrocytosis and low serum erythropoietin level. To date, only rare cases of such mutations have been reported in the JAK2 exon 12. Using computer-based structural modelling we propose that this mutation causes the loss of the JAK2 auto-inhibition step, leading to the constitutive activation of JAK2 tyrosine kinase-dependent activity. Our model-based hypothesis provides a useful approach for the investigation of the phenotype-genotype relationship in myeloproliferative disorders involving JAK2.
引用
收藏
页码:986 / 990
页数:5
相关论文
共 12 条
[1]   Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis [J].
Cazzola, Mario .
HAEMATOLOGICA, 2007, 92 (12) :1585-+
[2]   Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains [J].
Chen, M ;
Cheng, A ;
Candotti, F ;
Zhou, YJ ;
Hymel, A ;
Fasth, A ;
Notarangelo, LD ;
O'Shea, JJ .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (03) :947-956
[3]   The conformational plasticity of protein kinases [J].
Huse, M ;
Kuriyan, J .
CELL, 2002, 109 (03) :275-282
[4]   CYTOKINE RECEPTOR SIGNALING [J].
IHLE, JN .
NATURE, 1995, 377 (6550) :591-594
[5]   Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].
Levine, RL ;
Wadleigh, M ;
Cools, J ;
Ebert, BL ;
Wernig, G ;
Huntly, BJP ;
Boggon, TJ ;
Wlodarska, L ;
Clark, JJ ;
Moore, S ;
Adelsperger, J ;
Koo, S ;
Lee, JC ;
Gabriel, S ;
Mercher, T ;
D'Andrea, A ;
Fröhling, S ;
Döhner, K ;
Marynen, P ;
Vandenberghe, P ;
Mesa, RA ;
Tefferi, A ;
Griffin, JD ;
Eck, MJ ;
Sellers, WR ;
Meyerson, M ;
Golub, TR ;
Lee, SJ ;
Gilliland, DG .
CANCER CELL, 2005, 7 (04) :387-397
[6]   Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation [J].
Lindauer, K ;
Loerting, T ;
Liedl, KR ;
Kroemer, RT .
PROTEIN ENGINEERING, 2001, 14 (01) :27-37
[7]   Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways [J].
Luo, H ;
Rose, P ;
Barber, D ;
Hanratty, WP ;
Lee, S ;
Roberts, TM ;
DAndrea, AD ;
Dearolf, CR .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (03) :1562-1571
[8]   The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2 [J].
Reiter, A ;
Walz, C ;
Watmore, A ;
Schoch, C ;
Blau, I ;
Schlegelberger, B ;
Berger, U ;
Telford, N ;
Aruliah, S ;
Yin, JA ;
Vanstraelen, D ;
Barker, HF ;
Taylor, PC ;
O'Driscoll, A ;
Benedetti, F ;
Rudolph, C ;
Kolb, HJ ;
Hochhaus, A ;
Hehlmann, R ;
Chase, A ;
Cross, NCP .
CANCER RESEARCH, 2005, 65 (07) :2662-2667
[9]   Regulation of the Jak2 tyrosine kinase by its pseudokinase domain [J].
Saharinen, P ;
Takaluoma, K ;
Silvennoinen, O .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (10) :3387-3395
[10]   Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain [J].
Saharinen, P ;
Vihinen, M ;
Silvennoinen, O .
MOLECULAR BIOLOGY OF THE CELL, 2003, 14 (04) :1448-1459